Biotech Patent explained: this guide covers what it means, who it applies to, the step-by-step process, documents required, fees, due dates and penalties in India — so you can stay compliant with confidence and avoid costly mistakes.
The Guidelines for Examination of Biotechnology Applications for Patent (March 2013) set out how the Patent Office examines gene, protein, cell, vaccine and diagnostic inventions. Paragraphs 1 to 5 give the purpose, a history of biotech patenting in India, the biodiversity issues, the sections of the Act that matter and a list of the kinds of claim the Office usually meets.
The Guidelines aim at uniform and consistent examination and do not constitute rule making: the Act and Rules prevail (para 1). They supplement the Manual (para 3). Twelve provisions are emphasised, from section 2(1)(j) to section 10(5) (para 4). Biotechnology claims fall into ten families, from polynucleotides and polypeptides to host cells, antibodies and diagnostic tests (para 5). The Guidelines are the Patent Office's guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as now in force prevail.
The Office revises its guidelines, so check the current version on ipindia.gov.in. This document dates from March 2013 and describes the Biological Diversity Act, 2002 as it then stood; the Act as amended in 2023 should be checked for what is required now. For a short summary of the law, see our post on patents for biotech inventions. A specification for a biotechnology invention can be prepared through patent drafting and filing.
Why the Guidelines exist (paragraph 1)
The Guidelines describe classical biotechnology (fermentation, isolating antibiotics from moulds) and modern biotechnology (genetic engineering from the late 1970s, giving products such as human insulin and monoclonal antibodies). Biotechnological inventions include gene engineering products and processes, methods of producing organisms, isolation of micro-organisms, mutation methods, cultures, plasmids and processes for monoclonal antibodies.
They list the issues of concern: novelty, obviousness, industrial applicability, extent of disclosure and clarity of claims, plus special issues such as moral and ethical concerns, environmental safety, expressed sequence tags, cloning of farm animals, stem cells and gene diagnostics. The stated purpose is uniform and consistent examination. The paragraph ends with the status statement: the Guidelines are not rule making, the Act and Rules prevail, and the Guidelines are subject to revision in light of court decisions, amendments and stakeholder inputs.
A brief history of biotech patenting in India (paragraph 2)
TaxClue's summary of the Guidelines' account:
| Period | What the Guidelines say |
|---|---|
| Until 2002 | Office practice did not grant patents for living entities of natural or artificial origin, biological or replicating materials, substances derived from them or processes for producing living substances including nucleic acids; patents could be granted for processes producing non-living substances by chemical, bioconversion and microbiological processes |
| 2002, court ruling | The Calcutta High Court in Dimminaco AG v Controller of Patents and Designs, as cited in the Guidelines, held that a process whose end product contains living micro-organisms can be a manner of manufacture where the product is a new commercial article; the case concerned a live poultry vaccine |
| 2002, amendment | The Patents (Amendment) Act, 2002 brought biochemical, biotechnological and microbiological processes within chemical processes, and redefined "invention" as a new product or process involving an inventive step and capable of industrial application |
| 17 December 2001 and 2002 | India joined the Budapest Treaty, and section 10 was amended to provide for deposit of biological material and reference to it in the application |
| 2005 | The amendment opened product patents in all fields of technology including biotechnology, with exceptions to protect the public interest, and recognised International Depository Authorities |
The Guidelines' account of the Dimminaco ruling mentions the vendibility test: whether the invention produces a vendible item, meaning something that can be bought and sold. That test explains why the Office changed its practice for living end products.
Biodiversity issues (paragraph 3)
The Guidelines describe section 6 of the Biological Diversity Act, 2002, in force from 1 July 2004: obtaining intellectual property rights from the use of biological resources in India is subject to approval of the National Biodiversity Authority. In 2005 section 10 of the Patents Act was amended to make disclosure of the source and geographical origin of biological material mandatory where it is used in an invention, and a declaration regarding the required permission was inserted in Form 1 of the Rules. These issues are called an essential element of examination in biotechnology.
This is how the document stood in 2013. The Act as amended in 2023 and Form 1 as substituted in 2024 should be checked; see our post on the forms as substituted in 2024. Paragraph 3 closes by saying the Guidelines supplement the Manual.
The provisions covered (paragraph 4)
| Provision | Subject in the Guidelines |
|---|---|
| Section 2(1)(j) | Novelty, inventive step and industrial applicability of products or processes |
| Section 3(b) | Inventions contrary to morality or seriously prejudicial to life, health or the environment |
| Section 3(c) | Discovery of any living thing or non-living substance occurring in nature |
| Section 3(d) | New form of a known substance without enhanced efficacy; new property or use |
| Section 3(e) | Mere admixture |
| Section 3(h) | Methods of agriculture and horticulture |
| Section 3(i) | Methods of treatment and diagnosis |
| Section 3(j) | Plants and animals other than micro-organisms, and essentially biological processes |
| Section 3(k) | Computer programmes per se, algorithms, mathematical methods |
| Section 3(p) | Inventions which are in effect traditional knowledge |
| Section 10(4) | Sufficiency of disclosure and the method of performing the invention |
| Section 10(5) | Unity of invention, clarity, succinctness and support of claims |
Each gets its own paragraph; later articles in this series take them in order, and our posts on prior art, novelty and sequence claims and the section 3(b) to (e) exclusions come next.
The kinds of claims (paragraph 5)
The Guidelines list the claims usually seen in biotechnology applications:
- polynucleotides or gene sequences, as product or process;
- polypeptides or protein sequences, as product or process;
- vectors such as plasmids;
- gene constructs or cassettes and gene libraries;
- host cells, micro-organisms and stem cells, and transgenic cells;
- plant and animal tissue culture;
- pharmaceutical or vaccine compositions comprising micro-organisms, proteins or polynucleotides;
- antibodies and antigen-binding fragments, monoclonal or polyclonal;
- diagnostic kits and tests;
- diagnostic tests such as detection of a mutation in a gene or protein associated with a condition.
The Guidelines say they begin with this list to make later discussion of novelty and inventive step easier to follow, and that wording, clarity, support and sufficiency are discussed under their own headings.
What the examiner checks, and what to file
| Examiner's question | What the applicant should show |
|---|---|
| Which kind of claim is this, and does the family of claims make sense together? | Claims set out by family (sequence, vector, cell, composition, antibody, diagnostic) and linked by the same invention |
| Is the biological material used from India, and is source and origin stated? | The source and geographical origin in the specification and the Form 1 declaration, as in force |
| Is the material deposited where needed? | Deposit with an International Depository Authority and a reference in the specification |
| Is a sequence listing filed? | A sequence listing in the form the Rules require, as the next article explains |
A worked example (invented)
Jeevan Genomics files claims to a gene sequence, a vector carrying it, a host cell transformed by the vector, a vaccine composition and a diagnostic kit. The examiner's first report asks which claims form the invention, for the source of the gene and for the Form 1 declaration. Jeevan states in the specification that the gene was obtained from a strain isolated in another country and names the country, corrects the declaration, and explains that the vector, host cell, vaccine and kit all rely on the one new gene. The objections were procedural, and they are answered by stating the origin clearly and identifying the common feature.
Common lapses
- Leaving source and origin out of the specification when biological material is used.
- Not identifying which claims are the product and which the process.
- Treating the 2013 text on biodiversity as a statement of current law.
- Filing a wide family of claims with no unifying feature.
Need help with a biotechnology patent filing?
Biotechnology specifications raise questions of source, deposit and claim structure that are better settled before filing. Our team can review your draft against these paragraphs. See patent drafting and filing, and read next about the section 3(b), (c), (d) and (e) exclusions in the same Guidelines.
Key takeaways
- The Guidelines aim at uniform examination; the Act and Rules prevail.
- Twelve provisions of the Act are emphasised, from section 2(1)(j) to section 10(5).
- Biotech claims fall into ten families, from sequences to diagnostic tests.
- The 2013 account of biodiversity law predates the 2023 amendment of the Act.
- Source and origin of biological material is an essential part of examination.
Read next
- Biotechnology Patent Guidelines 2013, paragraphs 6 to 9: novelty, sequence claims and inventive step
- Biotechnology Patent Guidelines 2013, paragraphs 10 to 13: section 3(b), (c), (d) and (e)
- Biotechnology Patent Guidelines 2013, paragraphs 19 to 21: sufficiency, deposit and biodiversity
- Patent for Biotech Inventions: Micro-organisms and Genes
Disclaimer: Based on the manuals and guidelines published by the Office of the Controller General of Patents, Designs and Trade Marks that are named in the article, as consulted on 4 October 2026. They are guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as amended (including the 2024 amendment rules) prevail, and the current versions on ipindia.gov.in should be checked. This article is general information, not legal advice; check the official text before acting.